このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Study of KITE-363 in Participants With Autoimmune Neurologic Diseases That Did Not Respond to Usual Treatment (HERMOSA-2)

2026年11月16日 更新者:Kite, A Gilead Company

A Phase 1, Open-label, Multiregional, Multicenter, Basket Study Evaluating the Safety and Efficacy of KITE-363, an Autologous Anti-CD19/CD20 CAR T-cell Therapy in Participants With Relapsed/Refractory Autoimmune Neurologic Diseases

This study will have two Phases: Phase 1a and Phase 1b. The goals of this clinical study are to learn more about the study drug KITE-363, by evaluating its safety, tolerability and efficacy in participants with relapsed/refractory autoimmune neurologic diseases.

The primary objectives of this study are:

  • To evaluate the safety and tolerability of KITE-363 in participants with autoimmune neurologic diseases
  • To determine the recommended dose for Phase 1b
  • To evaluate the safety and preliminary efficacy of KITE-363 in participants with autoimmune neurologic diseases

調査の概要

状態

募集

条件

介入・治療

研究の種類

介入

入学 (推定)

57

段階

  • フェーズ 1

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究場所

    • California
      • Newport Beach、California、アメリカ、92663
        • 募集
        • Hoag Memorial Hospital Presbyterian
      • Palo Alto、California、アメリカ、94304
        • 募集
        • Stanford Neuroscience Health Center
    • New York
      • New York、New York、アメリカ、10032
        • 募集
        • Columbia University Irving Medical Center
    • Utah
      • Salt Lake City、Utah、アメリカ、84143
        • 募集
        • LDS Hospital - Intermountain Health
    • Washington
      • Seattle、Washington、アメリカ、98109
        • 募集
        • Fred Hutchinson Cancer Center
    • New South Wales
      • Sydney、New South Wales、オーストラリア、2139
        • 募集
        • Concord Repatriation General Hospital
      • Westmead、New South Wales、オーストラリア、2145
        • 募集
        • Corner Hawkesbury Road and Darcy Road
      • Montreal、カナダ、H3T 1E2
        • 募集
        • Jewish General Hospital
      • Montreal、カナダ、H1T 2M4
        • 募集
        • Centre Intégré Universitaire de Sante et Services Sociaux de L'Est de I'lle de Montreal / installation Hopital Maisonneuve-Rosemont
      • Ottawa、カナダ、K1H 8L6
        • 募集
        • The Ottawa Hospital - General Campus

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年~75年 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Key Inclusion Criteria:

  • Age 18 through 65 for relapsing forms of MS, 18 through 75 for progressive forms of MS, above 18 years of age for MG and CIDP.

  • Reproductive status-related eligibility and contraception requirements:

    • Individuals must agree to use protocol-specified method(s) of contraception where applicable

Inclusion Criteria for multiple sclerosis (MS):

MS (Relapsing and progressive forms):

  • Diagnosed with MS according to the 2017 revision of the McDonald diagnostic criteria

Relapsing forms of MS (relapsing-remitting multiple sclerosis (RRMS), active secondary-progressive multiple sclerosis (aSPMS)):

  • Inadequate response to previous therapies is defined as evidence of breakthrough disease activity within 12 months prior to screening while on high efficacy disease-modifying therapy (DMT) OR Inadequate response to previous therapies defined as intolerance to ≥ 2 DMTs due to side effects prohibiting the chronic use of the DMT.
  • Expanded Disability Status Scale (EDSS) 0 to 6.0

Progressive forms of MS (primary-progressive multiple sclerosis (PPMS) and non-active secondary-progressive multiple sclerosis (naSPMS)):

  • Inadequate response to previous therapies is defined as evidence of disease progression within 12 months prior to screening despite standard of care therapy for naSPMS or despite ocrelizumab, where available, for PPMS
  • Absence of clinical relapses for at least 24 months
  • No evidence of Gadolinium enhancing (GadE+) on magnetic resonance imaging (MRI) brain at screening or baseline
  • EDSS of 3 to 6.5 who are ambulatory

Inclusion Criteria for myasthenia gravis (MG):

  • Documentation of autoantibodies against acetylcholine receptor (AChR), muscle-specific kinase (MuSK), or low-density lipoprotein receptor-related protein 4 (LRP4)
  • Diagnosis of MG with generalized weakness meeting criteria as defined by the Myasthenia Gravis Foundation of American (MGFA) classification of II- IV at screening
  • Myasthenia Gravis Activities of Daily Living (MG-ADL) score ≥ 6 (> 50% of the total score due to non-ocular symptoms)
  • Quantitative Myasthenia Gravis (QMG) score ≥ 10
  • Inadequate response to previous therapies while taking at least 2 classes of immunosuppressants (ie, steroids, azathioprine (AZA), mycophenolate mofetil (MMF), intravenous immunoglobulin (IVIg), biologics (eg, rituximab, anti-FcRN class, and anti-complement class))
  • Thymectomy allowed if completed ≥ 12 months prior to screening

Inclusion Criteria for chronic inflammatory demyelinating polyneuropathy (CIDP):

  • Probable or definite CIDP as defined by the 2010 European Federation of Neurological Societies/Peripheral Nerve Society (EFNS/PNS) criteria, relapsing or progressive forms. Individuals with confirmed IgG4 paranodal antibodies (eg, NF155, CNTN1, Caspr1) are eligible if they meet EFNS/PNS 2010 criteria

    • For the Phase 1b CIDP cohort, diagnosis will be confirmed by independent adjudication once the adjudication committee is established and operational
  • CIDP Disease Activity Status (CDAS) score ≥ 3 at screening and confirmed at the final pre treatment assessment prior to infusion

  • Inflammatory neuropathy cause and treatment (INCAT) score ≥ 3 at screening and confirmed at one of more protocol-defined baseline assessments during the Extended Screening Period with Observational Run-in; individuals must also continue to meet clinical eligibility criteria at the final pre-treatment assessment prior to infusion

  • Inadequate response to previous therapies despite adequate trial of standard of care therapy (≥ 8-12 weeks at standard dosing with stable regimen of either steroids, IVIg, SCIg, plasmapheresis exchange (PLEX), rituximab or anti-FcRN) and either failure, intolerance, or contraindication to at least one additional standard therapy (ie, steroids, IVIg, subcutaneous immunoglobulin (SCIg), plasmapheresis exchange (PLEX), rituximab, or anti FcRN), unless medically inappropriate OR Unable to tolerate standard of care resulting in discontinuation due to side effects, with ongoing disease activity

  • Except for nodal/paranodal CIDP, historical documentation of objective improvement in the past 24 months while on IVIg, SCIg, PLEX, or anti-FcRN OR Historical documentation of objective disease worsening in the past 24 months when IVIg, SCIg, PLEX, or anti-FcRN has been reduced or interrupted

Key Exclusion Criteria:

  • History or presence of central nervous system (CNS) or peripheral nervous system disorders before enrollment that may impact cognition, strength, or cause weakness
  • History of autologous or allogeneic stem cell transplant and/or organ transplant
  • History of hemophagocytic lymphohistiocytosis (HLH) or macrophage activation syndrome (MAS)

Exclusion Criteria for MS:

  • Cohort 1 or 2; inability to complete 9-hole Peg Test (9-HPT) in < 240 seconds and Timed 25 foot Walk (T25FW) < 150 seconds
  • History of hypersensitivity to parenteral administration of gadolinium-based contrast agents
  • Any renal condition that would preclude the administration of gadolinium (for the relapsing forms of MS and progressive forms of MS)
  • Any contraindication to lumbar puncture (LP) (for the relapsing forms of MS and progressive forms of MS)

Exclusion Criteria for MG:

  • Current myasthenic crisis not effectively controlled within 2 weeks before enrollment
  • Thymectomy performed within 12 months of baseline

Exclusion Criteria for CIDP:

  • Pure sensory CIDP and focal CIDP
  • Polyneuropathy of other causes

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:非ランダム化
  • 介入モデル:順次割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Phase 1a: KITE-363 (Dose Escalation) With Lymphodepleting Chemotherapy

Participants with relapsing forms of multiple sclerosis (RMS), progressive forms of multiple sclerosis (PMS), myasthenia gravis (MG), and/or chronic inflammatory demyelinating polyneuropathy (CIDP) will receive lymphodepleting chemotherapy with cyclophosphamide and fludarabine followed by infusion of KITE-363 chimeric antigen receptor (CAR) transduced autologous T cells at a single dose level, with different participants receiving sequential dose-escalation levels to find the Phase 1b recommended dose.

Administered intravenously

Administered intravenously

A single infusion of CAR-transduced autologous T cells administered as intravenous infusion.

実験的:Phase 1a: KITE-363 (Dose Escalation) Without Lymphodepleting Chemotherapy

Participants with RMS, PMS, MG, and/or CIDP will receive infusion of KITE-363 CAR transduced autologous T cells at a single dose level, with different participants receiving sequential dose-escalation levels to find the Phase 1b recommended dose.

A single infusion of CAR-transduced autologous T cells administered as intravenous infusion.

実験的:Phase 1b: KITE-363 (Dose Expansion)

Participants with RMS, PMS, MG, and/or CIDP will receive lymphodepleting chemotherapy with cyclophosphamide and fludarabine followed Phase 1a recommended dose of KITE-363 CAR T cells.

Administered intravenously

Administered intravenously

A single infusion of CAR-transduced autologous T cells administered as intravenous infusion.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
第1a相:KITE-363の投与後に用量制限毒性(DLT)を経験した参加者の割合
時間枠:最大28日間
最大28日間
Phase 1b:再発型MS(RRMSおよびaSPMS):12週目におけるMRI上の新規および/または増大したT2病変の数
時間枠:週 12
週 12
Phase 1a: Percentage of Participants Experiencing Treatment-emergent Adverse Event (TEAEs)
時間枠:Up to 3 years
Up to 3 years
Phase 1b: (All Cohorts) Percentage of Participants Experiencing TEAEs
時間枠:Up to 3 years
Up to 3 years
Phase 1b: Relapsing Forms of MS (RRMS) and Active Secondary-progressive Multiple Sclerosis (aSPMS): Number of New T1 Gadolinium Enhancing (GadE+) Lesions on Magnetic Resonance Imaging (MRI) at Week 12
時間枠:Week 12

This will be reported in participants with relapsing forms of Multiple Sclerosis MS (RRMS) and (aSPMS).

Week 12
Phase 1b: Progressive Forms of MS (PPMS) and Non-active Secondary-progressive Multiple Sclerosis (naSPMS): Time to Onset of Confirmed Disability Progression Over 12 Weeks (CDP-12)
時間枠:Up to 3 years
Up to 3 years
Phase 1b: Myasthenia Gravis (MG): Proportion of Participants of MG Activities of Daily Living (MG-ADL) Responders
時間枠:Up to 3 years

The MG-ADL is a scale to measure the functional impact of MG on daily activities. The total score ranges from 0 to 24, with higher scores indicating greater disability and disease burden.

Up to 3 years
Phase 1b: CIDP: Proportion of Participants with a ≥ 2 Points Improvement from Baseline in aINCAT Score at Week 24, in the Absence of CIDP Rescue Therapy or Initiation of New Maintenance Immunomodulatory Therapy
時間枠:Up to 3 years

Clinical improvement will be analyzed using adjusted inflammatory neuropathy cause and treatment (aINCAT) scale. The INCAT score is a clinician administered tool used to assess functional disability in participants with chronic inflammatory demyelinating polyneuropathy (CIDP). The total scores range from 0 to 10, higher scores indicating greater disability and lower score would indicate clinical improvement.

Up to 3 years

二次結果の測定

結果測定
メジャーの説明
時間枠
血液中のT細胞レベル
時間枠:最大2年間
最大2年間
薬物動態:血液中のキメラ抗原受容体(CAR)T細胞のレベル
時間枠:最大2年間
最大2年間
薬力学パラメーター: 血液中のB細胞レベル
時間枠:最大2年間
最大2年間
薬力学パラメータ:血液中の疾患特異的バイオマーカーおよび自己抗体のレベル
時間枠:最大2年間
最大2年間
血液中のKITE-363 CAR T細胞に対する抗体を有する参加者の割合
時間枠:最大2年間
最大2年間
Relapsing forms of MS (RRMS and aSPMS): Annual Relapse Rate
時間枠:Up to 3 years

Proportion of participants with annual relapse.

Up to 3 years
Relapsing Forms of MS (RRMS and aSPMS): Proportion of Participants With CDP-12
時間枠:Up to 3 years
Up to 3 years
Relapsing Forms of MS (RRMS and aSPMS): Proportion of Participants With CDP-24
時間枠:Up to 3 years
Up to 3 years
Relapsing Forms of MS (RRMS and aSPMS): Time to Onset of CDP-12
時間枠:Up to 3 years
Up to 3 years
Relapsing Forms of MS (RRMS and aSPMS): Time to Onset of CDP-24
時間枠:Up to 3 years
Up to 3 years
Progressive forms of MS (PPMS and naSPMS): Proportion of Participants with No Evidence of Disease Activity (NEDA)
時間枠:Up to 3 years
Up to 3 years
Relapsing Forms of MS (RRMS and aSPMS): Change From Baseline in Expanded Disability Status Scale (EDSS) Score Over Time
時間枠:Up to 3 years

EDSS is scale used to measure disability and disease progression in participants with MS. It ranges from 0 (normal neurological exam) to 10 (death due to MS) in 0.5-point increments.

Up to 3 years
Relapsing Forms of MS (RRMS and aSPMS): Change From Baseline in Timed 25-foot Walk (T25FW) Score Over Time
時間枠:Up to 3 years

The T25FW is a performance-based measure used in people with MS to assess walking speed and mobility. Lower times indicate better walking ability, while longer times reflect greater impairment.

Up to 3 years
Relapsing Forms of MS (RRMS and aSPMS): Change From Baseline in 9-hole Peg Test Dominant/Non-dominant (9-HPT D/ND) Score Over Time
時間枠:Up to 3 years

The 9-HPT assesses hand dexterity and fine motor function by timing how long it takes a participant to place and remove nine pegs from a board. Faster times indicate better function, while slower times reflect greater disability.

Up to 3 years
Relapsing Forms of MS (RRMS and aSPMS): Change From Baseline in Symbol Digit Modalities Test (SDMT) Score Over Time
時間枠:Up to 3 years

SDMT is a performance-based cognitive assessment to measure information processing speed. The score is the number of correct responses completed in the time limit, with higher scores indicating better cognitive processing speed.

Up to 3 years
Progressive Forms of MS (PPMS and naSPMS): Proportion of Participants with CDP-12
時間枠:Up to 3 years
Up to 3 years
Progressive Forms of MS (PPMS and naSPMS): Proportion of Participants with CDP-24
時間枠:Up to 3 years
Up to 3 years
Progressive forms of MS (PPMS and naSPMS): Time to Onset of CDP-24
時間枠:Up to 3 years
Up to 3 years
Progressive forms of MS (PPMS and naSPMS): Number of new and Enlarging T2 Lesions on MRI
時間枠:Up to 3 years
Up to 3 years
Relapsing forms of MS (RRMS and aSPMS): Percentage of Participants With NEDA
時間枠:Up to 3 years
Up to 3 years
Progressive forms of MS (PPMS and naSPMS): Change From Baseline in EDSS Over Time
時間枠:Up to 3 years

EDSS is scale used to measure disability and disease progression in participants with MS. It ranges from 0 (normal neurological exam) to 10 (death due to MS) in 0.5-point increments.

Up to 3 years
Progressive forms of MS (PPMS and naSPMS): Change From Baseline in T25FW Over Time
時間枠:Up to 3 years

The T25FW is a performance-based measure used in people with MS to assess walking speed and mobility. Lower times indicate better walking ability, while longer times reflect greater impairment.

Up to 3 years
Progressive forms of MS (PPMS and naSPMS): Change From Baseline in 9-HPT D/ND Over Time
時間枠:Up to 2 years

The 9-HPT assesses hand dexterity and fine motor function by timing how long it takes a participant to place and remove nine pegs from a board. Faster times indicate better function, while slower times reflect greater disability.

Up to 2 years
Progressive forms of MS (PPMS and naSPMS): Change From Baseline in SDMT Over Time
時間枠:Up to 3 years

SDMT is a performance-based cognitive assessment to measure information processing speed. The score is the number of correct responses completed in the time limit, with higher scores indicating better cognitive processing speed.

Up to 3 years
MG: Proportion of Participants With at Least a 2-Point or 5 Point Improvement in MG-ADL Score up to Week 24
時間枠:Up to 24 weeks

The MG-ADL is a scale to measure the functional impact of MG on daily activities. The total score ranges from 0 to 24, with higher scores indicating greater disability and disease burden.

Up to 24 weeks
MG: Change From Baseline in MG-ADL Score at Week 24
時間枠:Baseline, Week 24

The MG-ADL is a scale to measure the functional impact of MG on daily activities. The total score ranges from 0 to 24, with higher scores indicating greater disability and disease burden.

Baseline, Week 24
MG: Proportion of Participants With Minimal Symptom Expression (MG-ADL Score of 0 or 1 Point)
時間枠:Up to 3 years

The MG-ADL is a scale to measure the functional impact of MG on daily activities. The total score ranges from 0 to 24, with higher scores indicating greater disability and disease burden.

Up to 3 years
MG: Proportion of Participants With at Least a 3-point or 5-point Improvement in Medical Research Council (QMG) Score up to Week 24
時間枠:Baseline, Week 24

The QMG test is a standardized quantitative strength scoring system developed specifically for MG. The total QMG score is the sum of the scores for 13 items, with a possible maximum score of 39. A higher score indicates more severe disease involvement, while a lower score suggests less functional impairment.

Baseline, Week 24
MG: Change From Baseline in QMG Score to Week 24
時間枠:Baseline, Week 24

The QMG test is a standardized quantitative strength scoring system developed specifically for MG. The total QMG score is the sum of the scores for 13 items, with a possible maximum score of 39. A higher score indicates more severe disease involvement, while a lower score suggests less functional impairment.

Baseline, Week 24
MG: Proportion of Participants With at Least a 3-Point Improvement in MG-C Score up to Week 24
時間枠:Baseline, Up to 24 weeks

MG-C scale is a tool that measures disease severity in MG. The total score ranges from 0 to 50, with higher scores indicating greater impairment.

Baseline, Up to 24 weeks
Change From Baseline in MG-C Scale Score at Week 24
時間枠:Baseline, Week 24

MG-C scale is a tool that measures disease severity in MG. The total score ranges from 0 to 50, with higher scores indicating greater impairment.

Baseline, Week 24
MG: Number of Participants With Changes in Myasthenia Gravis Foundation of American Post-Intervention Status (MGFA-PIS), Including Minimal Manifestation, Complete Stable Remission, Pharmacologic Remission
時間枠:Up to 3 years

The MGFA-PIS is a standardized classification system which categorizes outcomes into distinct states such as complete stable remission (CSR), pharmacologic remission (PR), minimal manifestations (MM), improved, unchanged, worse, and exacerbation. CSR indicates no symptoms or signs for at least one year without therapy, while MM reflects minimal weakness without functional limitation.

Up to 3 years
CIDP: Proportion of Participants With a ≥ 1-point Improvement from Baseline in aINCAT Score at Week 24, in the Absence of CIDP Rescue Therapy or Initiation of New Maintenance Immunomodulatory Therapy
時間枠:Week 24

Clinical improvement will be analyzed using INCAT scale. The INCAT score is a clinician administered tool used to assess functional disability in participants with CIDP. The total scores range from 0 to 10, higher scores indicating greater disability and lower score would indicate improvement.

Week 24
Proportion of Participants With a ≥ 2-point Improvement from Baseline in aINCAT Score at Week 24
時間枠:Week 24

Clinical improvement will be analyzed using INCAT scale. The INCAT score is a clinician administered tool used to assess functional disability in participants with CIDP. The total scores range from 0 to 10, higher scores indicating greater disability and lower score would indicate improvement.

Week 24
Proportion of Participants Without aINCAT Deterioration and Without Requirement for CIDP Rescue or Maintenance Therapy Through Week 24
時間枠:Up to Week 24
Up to Week 24
Proportion of Participants With ≥ 1-point Improvement in INCAT Lower Limb Score from Baseline to Week 24, in the Absence of CIDP Rescue Therapy or Initiation of New Maintenance Immunomodulatory Therapy
時間枠:Baseline, up to Week 24

Clinical improvement will be analyzed using INCAT scale. The INCAT score is a clinician administered tool used to assess functional disability in participants with CIDP. The total scores range from 0 to 10, higher scores indicating greater disability and lower score would indicate improvement.

Baseline, up to Week 24
Proportion of Participants Transitioning from INCAT Lower Limb score ≥ 3 (Assistive Device) to ≤ 2 (Independent Ambulation) from Baseline to Week 24, in the Absence of CIDP Rescue Therapy or Initiation of New Maintenance Immunomodulatory Therapy
時間枠:Baseline, up to Week 24

The INCAT score is a clinician administered tool used to assess functional disability in participants with CIDP. The total scores range from 0 to 10, higher scores indicating greater disability and lower score would indicate improvement.

Baseline, up to Week 24
CIDP: Time to First aINCAT Deterioration
時間枠:Up to 3 years

INCAT is a clinician-administered tool used to assess functional disability in participants with CIDP. The total score ranges from 0 to 10, where higher scores indicate greater disability and lower score would indicate clinical improvement.

Up to 3 years
CIDP: Proportion of Participants With Evidence of Clinical Improvement
時間枠:Up to week 24

Clinical improvement will be analyzed using inflammatory Rasch-built overall disability scale (I-RODS) scale. I-RODS is a scale that assesses activity and participation limitations in people with CIDP. The score ranges from 0 to 48, with higher scores indicating better functional ability.

Up to week 24
CIDP: Change From Baseline Over Time in Adjusted INCAT Score
時間枠:Up to 3 years

INCAT is a tool used to assess functional disability in participants with CIDP. The total score ranges from 0 to 10, where higher scores indicate greater disability.

Up to 3 years
CIDP: Change From Baseline Over Time in 24-Item I-RODS Score
時間枠:Up to 3 years

I-RODS is a scale that assesses activity and participation limitations in people with CIDP. The score ranges from 0 to 48, with higher scores indicating better functional ability.

Up to 3 years
CIDP: Change From Baseline Over Time in Medical Research Council (MRC) Sum Score
時間枠:Up to 3 years

MRC Sum Score is a measure to assess muscle strength for people with CIDP. The score ranges from 0 to 60. Higher scores indicate better muscle strength, while lower scores reflect greater weakness.

Up to 3 years
CIDP: Change From Baseline Over Time in Timed Up and Go (TUG) Score
時間枠:Up to 3 years

TUG test is a measure of mobility, balance, and fall risk. The score is recorded in seconds; shorter times indicate better mobility, while longer times suggest impaired balance or gait.

Up to 3 years
CIDP: Change From Baseline Over Time in Mean Grip Strength
時間枠:Up to 3 years

Mean Grip Strength is a quantitative measure of hand and forearm muscle strength. Higher values indicate better muscle strength, while lower values reflect weakness or functional impairment.

Up to 3 years
Proportion of Participants With European Quality of Life 5-Dimension 5-Level Questionnaire (EQ-5D-5L)
時間枠:Up to 3 years

The EQ-5D-5L is a generic measure of health status captured on the day of assessment. Two components comprise the EQ-5D-5L: the EQ-5D descriptive system and the EQ visual analog scale (VAS). The descriptive system comprises 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) and is divided into 5 levels of severity: "no problems," "slight problems," "moderate problems," "severe problems," and "extreme problems." The EQ-5D-5L VAS is a vertical VAS for recording self-rated current HRQoL, and it ranges from 0, described as "the worst health you can imagine," to 100, described as "the best health you can imagine." EQ-5D-5L will be scored according to the published administration and scoring manual.

Up to 3 years
Proportion of Participants With Chronic Acquired Polyneuropathy Patient-reported Index (CAP-PRI)
時間枠:Up to 3 years

The CAP-PRI is a tool developed to assess the impact of chronic acquired polyneuropathy on participant's quality of life, capturing both physical and psychological symptoms from the participant's perspective. The scoring of the CAP-PRI is typically based on how participants rate their symptoms and overall health across various dimensions, such as sensory symptoms, motor function, pain, emotional well-being, and fatigue. Each dimension of the CAP-PRI is scored separately, and the results are summed up to give an overall score for the participant, with higher scores indicating greater severity or a worse quality of life. Each domain typically uses a Likert scale or similar ordinal scale, where participants rate their experience or symptoms on a scale from 0 to 5.

Up to 3 years
Proportion of Participants With Rasch-Transformed Fatigue Severity Scale (RT-FSS)
時間枠:Up to 3 years

The RT-FSS or FSS-7 is a refined version of the original 9-item Fatigue Severity Scale (FSS-9) designed to improve accuracy in measuring fatigue, particularly in participants with immune-mediated neuropathies. The original 7-point Likert scale was collapsed into a 4-point response category for the remaining items to fulfill strict linearity requirements. It is a linearly weighted scale, meaning its scores provide a more precise, interval-level measurement rather than just an ordinal ranking. It was specifically validated for conditions like Guillain-Barré syndrome and CIDP. This modified scale provides a more stable test-retest reliability. The scale is used to distinguish between different levels of fatigue impact on daily activities, though it may have a ceiling effect for patients with extremely severe symptoms.

Up to 3 years
Pharmacodynamics Parameters: Levels of Cytokines and Chemokines in Blood
時間枠:Up to 2 years

A panel of inflammatory, immuno-modulatory and effector molecules, including cytokines and chemokines, will be measured as units of concentration in serum (e.g. pg/ml) using ligand-based immunoassays such as MSD, Ella and O-link.

Up to 2 years

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • スタディディレクター:Kite Study Director、Kite, A Gilead Company

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2026年4月10日

一次修了 (推定)

2031年12月1日

研究の完了 (推定)

2031年12月1日

試験登録日

最初に提出

2025年12月12日

QC基準を満たした最初の提出物

2025年12月12日

最初の投稿 (実際)

2025年12月26日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月17日

QC基準を満たした最後の更新が送信されました

2026年11月16日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。